Intuitive Surgical (ISRG) Expected Q4 Revenue of $2.76B, Up 14.5% YoY
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9h ago
0mins
Source: seekingalpha
- Earnings Announcement: Intuitive Surgical is set to announce its Q4 earnings on January 22, with an expected EPS of $2.27, reflecting a 2.7% year-over-year increase, and projected revenue of $2.76 billion, up 14.5% year-over-year, indicating sustained growth potential.
- Performance Beat Record: Over the past two years, Intuitive Surgical has exceeded EPS and revenue estimates 100% of the time, showcasing its strong market performance and management capabilities, which further bolster investor confidence.
- Market Share and Innovation: Holding an 80% global market share in surgical robotics, Intuitive Surgical ensures its industry leadership through continuous innovation anchored by the da Vinci platform and a robust recurring revenue model.
- Stock Performance and Ratings: Despite strong fundamentals, the stock has declined about 13% over the past year, contrasting with the S&P 500's 13% gain, leading to mixed analyst ratings, with Seeking Alpha's Quant model rating it as Hold, cautioning about high valuations relative to peers.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 637.32 USD with a low forecast of 575.00 USD and a high forecast of 740.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 527.440
Low
575.00
Averages
637.32
High
740.00
Current: 527.440
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
